The application of oleuropein to ulcerative colitis cells was responsible for diminishing the expression of COX-2, caused by the reduction of existing interleukins such as IL-17, as well as diminishing other inflammatory markers such as TNF-α and TL-1β [41]. The gene discussed is IL17A; the disease is ulcerative colitis.